ZD6474 attenuates TGF-β1-induced fibrosis in human Tenon fibroblasts and inhibits neovascularization via AKT-mTOR signaling pathway.

[1]  Shidou Zhao,et al.  Mesenchymal stem cells combined with autocrosslinked hyaluronic acid improve mouse ovarian function by activating the PI3K-AKT pathway in a paracrine manner , 2022, Stem Cell Research & Therapy.

[2]  M. Martin-Fernandez.  Fluorescence Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer , 2022, Cancers.

[3]  Thomas Y. Hsueh,et al.  4-Acetylantroquinonol B Suppresses Prostate Cancer Growth and Angiogenesis via a VEGF/PI3K/ERK/mTOR-Dependent Signaling Pathway in Subcutaneous Xenograft and In Vivo Angiogenesis Models , 2022, International journal of molecular sciences.

[4]  R. Krishnan,et al.  Substrate stiffening promotes VEGF-A functions via the PI3K/Akt/mTOR pathway. , 2021, Biochemical and biophysical research communications.

[5]  H. Ameri,et al.  Visual Outcomes in Eyes with Neovascular Glaucoma and Anterior Segment Neovascularization Without Glaucoma. , 2021, American journal of ophthalmology.

[6]  M. Alam,et al.  Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study , 2021, BMC Ophthalmology.

[7]  M. Aihara,et al.  mTOR inhibitors potentially reduce TGF-β2-induced fibrogenic changes in trabecular meshwork cells , 2021, Scientific Reports.

[8]  Y. Shinmei,et al.  Expression of Vascular Endothelial Growth Factor-C in the Trabecular Meshwork of Patients with Neovascular Glaucoma and Primary Open-Angle Glaucoma , 2021, Journal of clinical medicine.

[9]  S. Pierdomenico,et al.  Epithelial-Mesenchymal Transition (EMT): The Type-2 EMT in Wound Healing, Tissue Regeneration and Organ Fibrosis , 2021, Cells.

[10]  Zhong Lin,et al.  Identification of key genes and pathways in scleral extracellular matrix remodeling in glaucoma: Potential therapeutic agents discovered using bioinformatics analysis , 2021, International journal of medical sciences.

[11]  Jian-Wen Gu,et al.  Aqueous Inflammation and Ischemia-Related Biomarkers in Neovascular Glaucoma with Stable Iris Neovascularization , 2020, Current eye research.

[12]  Y. Hua,et al.  EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[13]  Wei Wang,et al.  Vandetanib (ZD6474) induces antiangiogenesis through mTOR–HIF-1 alpha–VEGF signaling axis in breast cancer cells , 2018, OncoTargets and therapy.

[14]  Ke Liu,et al.  The emerging role of fibrocytes in ocular disorders , 2018, Stem Cell Research & Therapy.

[15]  D. Lu,et al.  Combined trabeculotomy-trabeculectomy using the modified Safer Surgery System augmented with MMC: its long-term outcomes of glaucoma treatment in Asian children , 2018, Graefe's Archive for Clinical and Experimental Ophthalmology.

[16]  M. Nutaitis,et al.  Efficacy of selective laser trabeculoplasty following incisional glaucoma surgery. , 2018, International journal of ophthalmology.

[17]  Daisy Y. Shu,et al.  Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis , 2017, Progress in Retinal and Eye Research.

[18]  P. N. Prasad,et al.  Micellear Gold Nanoparticles as Delivery Vehicles for Dual Tyrosine Kinase Inhibitor ZD6474 for Metastatic Breast Cancer Treatment. , 2017, Langmuir : the ACS journal of surfaces and colloids.

[19]  M. Slabaugh,et al.  Use of Anti-VEGF Agents in Glaucoma Surgery , 2017, Journal of ophthalmology.

[20]  M. Kass,et al.  Anti-VEGF Injections and Glaucoma Surgery. , 2017, JAMA ophthalmology.

[21]  K. Youker,et al.  Epithelial to Mesenchymal Transition (EMT) and Endothelial to Mesenchymal Transition (EndMT): Role and Implications in Kidney Fibrosis. , 2017, Results and problems in cell differentiation.

[22]  D. Friedman,et al.  Primary open-angle glaucoma , 2016, Nature Reviews Disease Primers.

[23]  R. Mohan,et al.  Epigenetic Modification Prevents Excessive Wound Healing and Scar Formation After Glaucoma Filtration Surgery , 2016, Investigative ophthalmology & visual science.

[24]  Aiqun Zhang,et al.  Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer , 2015, Oncotarget.

[25]  R. Pandey,et al.  Evaluating the long-term efficacy of short-duration 0.1 mg/ml and 0.2 mg/ml MMC in primary trabeculectomy for primary adult glaucoma , 2015, Graefe's Archive for Clinical and Experimental Ophthalmology.

[26]  F. Medeiros,et al.  The pathophysiology and treatment of glaucoma: a review. , 2014, JAMA.

[27]  C. Porta,et al.  Targeting PI3K/Akt/mTOR Signaling in Cancer , 2014, Front. Oncol..

[28]  J. Crowston,et al.  Wound Healing Modulation in Glaucoma Filtration Surgery– Conventional Practices and New Perspectives: Antivascular Endothelial Growth Factor and Novel Agents (Part II) , 2014, Journal of current glaucoma practice.

[29]  R. Roskoski.  The ErbB/HER family of protein-tyrosine kinases and cancer. , 2014, Pharmacological research.

[30]  J. Fagin,et al.  Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. , 2013, Endocrine-related cancer.

[31]  T. Chikama,et al.  Matrix metalloproteinase and cytokine expression in Tenon fibroblasts during scar formation after glaucoma filtration or implant surgery in rats , 2013, Cell biochemistry and function.

[32]  C. K. Park,et al.  VEGF induces TGF-β1 expression and myofibroblast transformation after glaucoma surgery. , 2013, The American journal of pathology.

[33]  Leonard K. Seibold,et al.  Wound modulation after filtration surgery. , 2012, Survey of ophthalmology.

[34]  Xiaomin Lu,et al.  Intraoperative mitomycin C versus intraoperative 5-fluorouracil for trabeculectomy: a systematic review and meta-analysis. , 2012, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[35]  L. Moons,et al.  The role of different VEGF isoforms in scar formation after glaucoma filtration surgery. , 2010, Experimental eye research.

[36]  J. Crowston,et al.  Combined treatment with bevacizumab and 5-fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery. , 2010, Investigative ophthalmology & visual science.

[37]  W. Spileers,et al.  Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. , 2009, Investigative ophthalmology & visual science.

[38]  T. Klink,et al.  [Beyond TGF-beta: wound healing modulation in filtering glaucoma surgery]. , 2009, Klinische Monatsblatter fur Augenheilkunde.

[39]  B. Adegbehingbe,et al.  Intra-operative 5-FU in Glaucoma Surgery: A Nigerian Teaching Hospital Experience , 2008, Middle East African journal of ophthalmology.

[40]  S. Arora,et al.  Mitomycin C augmented glaucoma surgery: evolution of filtering bleb avascularity, transconjunctival oozing, and leaks , 2006, British Journal of Ophthalmology.

[41]  A. Jünemann,et al.  Comparative effects of TGF-beta 1 and TGF-beta 2 on extracellular matrix production, proliferation, migration, and collagen contraction of human Tenon's capsule fibroblasts in pseudoexfoliation and primary open-angle glaucoma. , 2005, Experimental eye research.

[42]  M. Rękas,et al.  [Subconjuctival application of 5-fluorouracil (5-FU) following surgical treatment of glaucoma with deep sclerectomy--indications, complications and initial evaluation of effectiveness]. , 2005, Klinika oczna.

[43]  G. Skuta,et al.  Wound Healing Modulation in Glaucoma Filtering Surgery , 2004, International ophthalmology clinics.

[44]  F. Grehn,et al.  [Control of wound healing after glaucoma surgery. Effect and inhibition of the growth factor TGF-beta]. , 2002, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[45]  F. Grehn,et al.  Steuerung der Wundheilung nach Glaukomchirurgie Wirkung und Hemmung des Wachstumsfaktors TGF-beta , 2002, Der Ophthalmologe.

[46]  P. Denk,et al.  Wundheilung nach filtrierenden Glaukomoperationen - eine Übersicht , 1999 .

[47]  R. Parrish,et al.  Wound healing in glaucoma filtering surgery. , 1987, Survey of ophthalmology.